Lancashire and South Cumbria
Formulary
10 Musculoskeletal and joint diseases
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents:
mlcsu.lscformulary@nhs.net
.
For more information about the formulary development process, please see:
https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
10-01-04 Acute attacks of gout
Colchicine
Formulary
Tablets 500 micrograms
MHRA: Colchicine: extremely toxic in overdose
Links
LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
LSCMMG: Primary Care Constipation Guidelines
MHRA advice regarding risk of serious hypersensitivity reactions
MHRA Drug Safety update July 2019: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
MHRA DSU April 2019: Belimumab (Benlysta): increased risk of serious psychiatric events seen in clinical trials
MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
MHRA: Colchicine: extremely toxic in overdose
MHRA: Febuxostat (Adenuric▼): stop treatment if signs or symptoms of serious hypersensitivity
MHRA: Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease
NICE CG147: Diverticular disease: diagnosis and management
NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
NICE HST25 - Lumasiran for treating primary hyperoxaluria type 1
NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
NICE TA164: Hyperuricaemia - febuxostat
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
NICE TA752:Belimumab for treating active autoantibody-positive systemic lupus erythematosus
NICE TA806: Belimumab for treating lupus nephritis (terminated appraisal)
Key
Full Site